The Move ECG hybrid smartwatch was announced by Withings in January, a feature to rival Apple’s. It was slated to launch in the second quarter of 2019 but it is already May and there’s no beep. Looks like we will have to wait for a while.
Here’s the official statement Withings provided to Wareable: “Move ECG is currently under review for CE and FDA clearance. While the timings of these approvals are out of the control of Withings and completely in the hands of regulators, we expect the process to be completed in the coming months, allowing us to get Move ECG onto the wrists of customers as soon as we can.” So, looks like Withings is waiting for the green signal from regulators in the US and Europe. The authorities need to make sure that the ECG feature can actually detect signs associated with heart-related issues, such as atrial fibrillation.
Even Apple had to go wait awhile before rolling out the feature. Though Apple launched the Watch Series 4 with the built-in ECG feature back in September 2018, the feature wasn’t switched on by Apple until the end of 2018. It took as long as March 2019 for the feature to reach more countries. The process is time consuming and Withings would want complete clearance from the regulators before they launch the feature.